Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial
Circulation · 2026
DOI: 10.1161/circulationaha.126.080999 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2026. Verfasst von Victorien Monguillon und 19 weiteren Autor:innen. Beteiligte Einrichtung: TIMI (Thrombolysis in Myocardial Infarction Study) Group, Boston, MA (V.M., N.A.M., E.A.B., J.-G.P., J.F.K., S.A.M., R.P.G., M.S.S., M.L.O.). Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lipoprotein(a), Anticholesteremic Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Amgen.
Abstract (Originalsprache)
BACKGROUND: Lp(a) (lipoprotein[a]) is a risk factor for coronary heart disease. Whether baseline Lp(a) identifies higher-risk patients who derive more benefit from evolocumab is not established in a population without previous myocardial infarction (MI) or stroke. METHODS: From June 2019 to November 2021, the VESALIUS-CV trial (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarctions or Stroke) enrolled patients with qualifying atherosclerosis or high-risk diabetes without previous MI or stroke and randomized them to evolocumab or placebo (median follow-up 4.6 years). In a prespecified analysis, Lp(a) was assessed at baseline in 7557 patients. Cox models were used to assess the adjusted risk of cardiovascular events by baseline Lp(a) in the placebo arm, and the efficacy of evolocumab by baseline Lp(a). The primary outcome of interest was the composite of major coronary events (coronary heart disease death, MI, or urgent coronary revascularization). RESULTS: Median age was 66 [interquartile range, 60–71] years, and 42.8% were women; median Lp(a) was 28 [interquartile range, 9–132] nmol/L. Higher baseline Lp(a) was associated with an increased risk of major coronary events (adjusted hazard ratio [HR adjusted ] per 100 nmol/L increase in Lp(a), 1.15 [95% CI, 1.05–1.26]; P =0.004), particularly for MI (HR adjusted , 1.23 [95% CI, 1.10–1.38]; P 105 nmol/L versus 61.1 mg/dL and 6.0 nmol/L in those with baseline Lp(a) ≤105 nmol/L. The relative reductions in the rate of major coronary events were 41% (HR, 0.59 [95% CI, 0.41–0.83]) in those with Lp(a) >105 nmol/L compared with 35% (HR, 0.65 [95% CI, 0.51–0.82]) in those below ( P -interaction=0.45 for Lp[a] modeled as continuous variable). The corresponding absolute reductions were 3.7% versus 2.5% ( P -interaction=0.09), corresponding to a number needed to treat of 28 versus 40 to prevent 1 major coronary event at 5 years. CONCLUSIONS: In patients with atherosclerosis or high-risk diabetes but without previous MI or stroke, Lp(a) was independently associated with an increased risk of major coronary events but not ischemic stroke. Evolocumab reduced the relative risk of major coronary events to a similar degree irrespective of baseline Lp(a), with a numerically greater absolute risk reduction in patients with elevated Lp(a). REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03872401.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- TIMI (Thrombolysis in Myocardial Infarction Study) Group, Boston, MA (V.M., N.A.M., E.A.B., J.-G.P., J.F.K., S.A.M., R.P.G., M.S.S., M.L.O.).
- Heart Vascular Institute (V.M., N.A.M., E.A.B., J.-G.P., J.F.K., S.A.M., R.B., R.P.G., M.S.S., M.L.O.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- Cardiology Division, Department of Medical Sciences, University of Turin and Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Italy (G.M.D.F.).
- Division of Endocrinology and Metabolism, St. Michael's Hospital, University of Toronto, Canada (L.A.L.).
- Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Brazil (J.C.N.).
- Department of Internal Medicine I, Medical University Innsbruck, Austria (C.E.).
ORCID-Profile: Victorien Monguillon, Nicholas A Marston, Erin A Bohula, Jeong-Gun Park, Sabina A Murphy, Gaetano M De Ferrari, Lawrence A Leiter, Jose C Nicolau, Peter Sinnaeve, Andrzej Budaj, Oleg Averkov, Ron Blankstein, Dragos Vinereanu, Robert P Giugliano, Marc S Sabatine, Michelle L O'Donoghue
Förderung
- Amgen
Zitieren
APA
Monguillon, V., Marston, N. A., Bohula, E. A., Park, J. G., Kuder, J. F., Murphy, S. A., De Ferrari, G. M., Leiter, L. A., Nicolau, J. C., Ebenbichler, C., Sinnaeve, P., Goudev, A., Budaj, A., Averkov, O., Tokgözoğlu, L., Blankstein, R., Vinereanu, D., Giugliano, R. P., Sabatine, M. S., & O'Donoghue, M. L. (2026). Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial. Circulation. https://doi.org/10.1161/circulationaha.126.080999
Vancouver
Monguillon V, Marston NA, Bohula EA, Park JG, Kuder JF, Murphy SA, et al. Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial. Circulation. 2026. doi:10.1161/circulationaha.126.080999
BibTeX
@article{Monguillon2026,
author = {Monguillon, Victorien and Marston, Nicholas A and Bohula, Erin A and Park, Jeong-Gun and Kuder, Julia F and Murphy, Sabina A and De Ferrari, Gaetano M and Leiter, Lawrence A and Nicolau, Jose C and Ebenbichler, Christoph and Sinnaeve, Peter and Goudev, Assen and Budaj, Andrzej and Averkov, Oleg and Tokgözoğlu, Lale and Blankstein, Ron and Vinereanu, Dragos and Giugliano, Robert P and Sabatine, Marc S and O'Donoghue, Michelle L},
title = {Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial},
journal = {Circulation},
year = {2026},
doi = {10.1161/circulationaha.126.080999}
}
EUVIMED